We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+32.51%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$427M
AUM Growth
+$52.8M
Cap. Flow
-$11.7M
Cap. Flow %
-2.75%
Top 10 Hldgs %
60.67%
Holding
34
New
2
Increased
10
Reduced
13
Closed
2

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$12M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$2.95M
3
IRON icon
Disc Medicine
IRON
+$2.56M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$19.9K
5
INSM icon
Insmed
INSM
+$17.9K

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$5.57M
2
TVTX icon
Travere Therapeutics
TVTX
+$4.94M
3
NTLA icon
Intellia Therapeutics
NTLA
+$4.66M
4
RLAY icon
Relay Therapeutics
RLAY
+$4.39M
5
VERV
Verve Therapeutics
VERV
+$2.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
26
Viking Therapeutics
VKTX
$3.75B
$6.05M 1.42%
325,284
+284
+0.1% +$3.71K
ADAP
27
DELISTED
Adaptimmune Therapeutics
ADAP
$4.04M 0.95%
5,095,912
– –
HARP
28
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$3.63M 0.85%
319,670
– –
IRON icon
29
Disc Medicine
IRON
$3.07B
$2.89M 0.68%
+50,000
New +$2.56M
VRDN icon
30
Viridian Therapeutics
VRDN
$2.61B
$2.18M 0.51%
100,000
-155,323
-61% -$2.45M
INZY
31
DELISTED
Inozyme Pharma
INZY
$1.38M 0.32%
323,813
-3,108
-1% -$11K
PHAT icon
32
Phathom Pharmaceuticals
PHAT
$743M
$639K 0.15%
70,000
-277,332
-80% -$2.39M
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
– –
-577,958
Closed -$5.57M
TVTX icon
34
Travere Therapeutics
TVTX
$6.19B
– –
-552,846
Closed -$4.94M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2023 Portfolio in Review

As of Q4 2023, MPM BioImpact held 34 positions worth $427M, up 14% from $375M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

MPM BioImpact's Q4 2023 filing shows 2 new, 10 increased, 13 reduced and 2 closed positions. Its largest new stake was ALX Oncology: 1,264,759 shares worth $18.8M. The largest sale was KalVista Pharmaceuticals, an estimated $5.57M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q4 2023 buy was ALX Oncology: 1,264,759 shares worth $18.8M.
  • MPM BioImpact added most to Morphic Holding, Inc. Common Stock in Q4 2023, an estimated $2.95M increase.
  • MPM BioImpact's biggest Q4 2023 reduction was Intellia Therapeutics, cutting an estimated $4.66M.
  • MPM BioImpact fully exited KalVista Pharmaceuticals in Q4 2023, selling an estimated $5.57M.
  • MPM BioImpact's ten largest holdings make up 61% of its $427M portfolio in Q4 2023.
  • MPM BioImpact opened 2 new positions and closed 2 in Q4 2023.
  • MPM BioImpact's portfolio value rose 14% quarter-over-quarter to $427M.

Based on MPM BioImpact's 13F filing for Q4 2023, filed 13 Feb 2024.